Discover.
Launch.
Build.
Transform.

GBT

GBT received accelerated approval from the U.S. Food and Drug Administration (FDA) for Oxbryta™ (voxelotor) for the treatment of sickle cell disease (SCD). The once-daily pill is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.

GBT

Thrive Earlier Detection

Cancer is often detected too late, when it has become challenging to treat and may have spread from one area in the body to others. Thrive is developing a high performance, highly targeted, blood-based screening approach, called CancerSEEK, designed to be implemented into routine medical care with the goal of identifying cancer at earlier stages across multiple cancer types.

THRIVE EARLIER DETECTION

bluebird bio

bluebird received conditional marketing authorization from the European Commission for ZYNTEGLO™, the first gene therapy approved for the treatment of transfusion-dependent β-thalassemia. This novel therapy has the potential to transform lives by offering patients the possibility of a transfusion-free future.

BLUEBIRD BIO

Maze Therapeutics

Dramatic advances in human genetics and functional genomics now enable us to decode the mysteries of genetic modifiers in a range of severe diseases. Today, we believe we can systematically identify genetic modifiers and turn these insights into medicines. The team at Maze Therapeutics has assembled a world-class team to realize this vision, including creative scientific pioneers, experienced company builders and biotech industry leaders.

MAZE THERAPEUTICS

Sage Therapeutics

Sage received approval from the U.S. Food and Drug Administration (FDA) for ZULRESSO™ (brexanolone) injection for the treatment of postpartum depression (PPD), the most common medical complication of childbirth. As the first and only treatment specifically indicated for PPD, new mothers and their families impacted by PPD now have a therapeutic option for this critical time in their lives.

SAGE THERAPEUTICS

Agios Pharmaceuticals

Agios has leveraged its core capabilities in cellular metabolism and precision medicine to build a product engine that is focused in the therapeutic areas of cancer and rare genetic diseases. With remarkable speed - about 10 years - Agios brought two therapeutics to the market. And now patients with acute myeloid leukemia have treatment options they didn’t have before.

AGIOS PHARMACEUTICALS
12

Years

53

Portfolio Companies

11

Marketed Products

1

Priority: Patients